Barclays Remains a Buy on Sanofi (SNYNF)
Confident Investing Starts Here:
Field covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, AstraZeneca, and Roche Holding AG. According to TipRanks, Field has an average return of -1.5% and a 39.02% success rate on recommended stocks.
In addition to Barclays, Sanofi also received a Buy from Bank of America Securities's Sachin Jain in a report issued yesterday. However, on the same day, J.P. Morgan maintained a Hold rating on Sanofi (Other OTC: SNYNF).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 minutes ago
- Business Wire
TC BANCSHARES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TC Bancshares, Inc.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of TC Bancshares, Inc. (OTC: TCBC) to Colony Bankcorp, Inc. (NYSE: CBAN). Under the terms of the proposed transaction, shareholders of TC will have the right to elect to receive either $21.25 in cash or 1.25 shares of Colony's common stock in exchange for each share of TC Bancshares common stock, subject to customary proration and allocation procedures such that approximately 20% of TC Bancshares common stock will be converted to cash consideration and the remaining 80% will be converted to Colony common stock. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Hamilton Spectator
an hour ago
- Hamilton Spectator
PharmAla Issues Q3 Financial Statements
TORONTO, July 25, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. ('PharmAla' or the 'Company') (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended May 31, 2025. All figures are reported in Canadian dollars. The Company's full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management's discussion and analysis can be accessed by visiting the Company's website at and its profile page on SEDAR+ at . 'The re-opening of PharmAla's domestic Canadian distribution has allowed us to execute as much volume in Q2 and Q3 as we did in all of the last fiscal year. The creation of our Prescriber's Portal has also allowed us to build a much closer relationship with our doctor customers, which we believe will serve us well moving forward,' said Nick Kadysh, CEO, PharmAla Biotech. 'As we move into the last quarter of Fiscal '24-25, we are incredibly pleased that a large shipment of LaNeo MDMA has arrived at our US distribution partner for delivery to a considerable group of clinical trial customers, most previously announced. PharmAla is also pleased to announce the completion of a manufacturing run in Australia for our 40mg LaNeo Capsules. These capsules were jointly manufactured for both Cortexa's use within Australia and PharmAla's use worldwide, and our improved manufacturing process should yield operational benefits well into the future.' Financial Highlights: 'Over the past quarter, our team has made exciting progress to ensure a reliable supply of pharmaceutical product for both researchers in clinical trials and patients in need of treatment,' said Will Avery, CFO, PharmAla Biotech. 'Our Prescriber Platform continues to empower physicians to access the MDMA and provide treatment for their patients and we look forward to additional clinical trial fulfillment to US and international customers in the near term, unburdened by cross-border trade issues.' About PharmAla PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla's research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a 'regulatory first' organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. For more information, please contact: Nicholas Kadysh Chief Executive Officer PharmAla Biotech Holdings Inc. Email: press@ Phone: 1-855-444-6362 Website: Neither the CSE nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'strategy', 'expects' or 'does not expect', 'intends', 'continues', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases or may contain statements that certain actions, events or results 'will be taken', 'will launch' or 'will be launching', 'will include', 'will allow', 'will be made' 'will continue', 'will occur' or 'will be achieved'. We direct readers to refer to the 'Caution Regarding Forward-Looking Statements' contained within the Company's management's discussion and analysis for the period ended May 31, 2025, as filed on Sedar+ . Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including but not limited to the risk factors discussed in the Company's management's discussion and analysis, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at , which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
Yahoo
an hour ago
- Yahoo
Why LVMH Rallied Today
Key Points LVMH rallied even as it posted continued revenue and profit declines. Still, it seems investors had anticipated even worse results. LVMH has top brands and was down 45% from highs, so investors may think the stock had bottomed. 10 stocks we like better than LVMH Moët Hennessy - Louis Vuitton › Shares of iconic brand house LVMH Moët Hennessy (OTC: LVMUY) rallied 5.3% on Friday, as of 3:28 p.m. ET. The luxury goods giant reported earnings last night for the first half of 2025, which showed continued year-over-year declines in revenue and profits. And yet, LVMH's stock rose, as results were apparently better than feared, and investors may believe the stock has already bottomed after being cut in half from its highs. Revenue and profits down but so was the stock Coming into the day, LVMH's stock had fallen 14.6% year to date and was over 45% below its all-time high. So, there was already a lot of pessimism around the stock, especially as the U.S.-China trade tensions had ratcheted up in the second quarter. Those are, essentially, LVMH's two most important markets. In the first half, LVMH's revenue declined 3% year over year on an organic basis, and operating profits fell 15%. While there were improvements in most of LVMH's product categories from Q1 to Q2, the company's core Fashion & Leather Goods segment got worse. LVMH (OTC: LVMUY) Revenue growth Wines & Spirits Fashion & Leather Goods Perfumes & Cosmetics Watches & Jewelry Selective Retailing Total First- quarter revenue (9%) (5%) (1%) 0% (1%) (3%) Second quarter (4%) (9%) 1% 0% 4% (4%) First half (7%) (7%) 0% 0% 2% (3%) Data source: LVMH 1H earnings release. The Fashion & Leather Goods segment accounts for nearly half of revenue and nearly 80% of operating profits. So the fact that that segment saw an accelerating decline wasn't good. That being said, LVMH stock rallied anyway, perhaps due to fears the recent tariffs would have led to an even greater downturn across the business. LVMH's brand-focused margins spur optimism Despite the revenue and margin decline, LVMH still made a healthy 22.6% operating margin, owing to its famous brands and diversification. And while the stock may not look "cheap" on an absolute basis of 20 times this year's earnings estimates, luxury goods tend to garner higher multiples in the market due to the perception of resilient demand among well-off customers. Of course, these companies aren't immune from the economic cycle, especially in China, which has been in recessionary conditions for three years now. So despite lukewarm, not-so-great results, it appears investors believe the recent decline has provided a solid bottom for the stock. LVMH remains an interesting turnaround story, as long as the economic climate in the U.S. and China improves. Should you invest $1,000 in LVMH Moët Hennessy - Louis Vuitton right now? Before you buy stock in LVMH Moët Hennessy - Louis Vuitton, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and LVMH Moët Hennessy - Louis Vuitton wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why LVMH Rallied Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
